Genprex Inc
GNPX
查看详细走势图
1.860USD
-0.030-1.59%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.87M总市值
0.03市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.59%
5天
-19.83%
1月
-33.57%
6月
-85.12%
今年开始到现在
-95.63%
1年
-95.99%
查看详细走势图
TradingKey Genprex Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Genprex Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名236/404位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价7.50。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Genprex Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
7.500
目标均价
+3230.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Genprex Inc亮点
亮点风险
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Genprex Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Genprex Inc简介
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
公司代码GNPX
公司Genprex Inc
CEOConfer (Ryan M)
网址https://www.genprex.com/
常见问题
Genprex Inc(GNPX)的当前股价是多少？
Genprex Inc(GNPX)的当前股价是 1.860。
Genprex Inc的股票代码是什么？
Genprex Inc的股票代码是GNPX。
Genprex Inc股票的52周最高点是多少？
Genprex Inc股票的52周最高点是55.000。
Genprex Inc股票的52周最低点是多少？
Genprex Inc股票的52周最低点是1.845。
Genprex Inc的市值是多少？
Genprex Inc的市值是1.87M。
Genprex Inc的净利润是多少？
Genprex Inc的净利润为-21.39M。
现在Genprex Inc(GNPX)的股票是买入、持有还是卖出？
根据分析师评级，Genprex Inc(GNPX)的总体评级为--，目标价格为7.500。
Genprex Inc(GNPX)股票的每股收益（EPS TTM）是多少
Genprex Inc(GNPX)股票的每股收益（EPS TTM）是55.092。
相关品种
